Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DSQA | ISIN: SE0009922305 | Ticker-Symbol: 1MH
Frankfurt
04.11.24
08:12 Uhr
11,280 Euro
+0,480
+4,44 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
ALLIGO AB Chart 1 Jahr
5-Tage-Chart
ALLIGO AB 5-Tage-Chart
GlobeNewswire (Europe)
34 Leser
Artikel bewerten:
(0)

Alligo AB: Interim Report Q3: 1 Jan-30 Sept 2024

PRESS RELEASE
October 24, 2024

Continued weak market - several initiatives for the future

Third quarter highlights

  • Revenue increased by 1.0 per cent to MSEK 2,143 (2,122). Organic growth was -3.0 per cent.
  • Gross margin was 40.5 per cent (41.6).
  • Adjusted EBITA decreased to MSEK 137 (191), corresponding to an adjusted EBITA margin of 6.4 per cent (9.0).
  • Operating profit decreased to MSEK 115 (175) and the operating margin was 5.4 per cent (8.2). Operating profit was charged with items affecting comparability of MSEK -6 (0).
  • Profit amounted to MSEK 60 (113).
  • Earnings per share amounted to SEK 1.20¹ (2.25¹).
  • Cash flow from operating activities increased to MSEK 116 (34).

First nine months highlights

  • Revenue decreased by -0.8 per cent to MSEK 6,744 (6,797). Organic growth was -4.1 per cent.
  • Gross margin was 40.6 per cent (40.7).
  • Adjusted EBITA decreased to MSEK 387 (519), corresponding to an adjusted EBITA margin of 5.7 per cent (7.6).
  • Operating profit decreased to MSEK 327 (470) and the operating margin was 4.8 per cent (6.9). Operating profit was charged with items affecting comparability of MSEK -14 (-4).
  • Profit amounted to MSEK 170 (305).
  • Earnings per share amounted to SEK 3.36¹ (6.01¹).
  • Cash flow from operating activities increased to MSEK 514 (467).

1)Before and after dilution.

Significant events during the third quarter

  • Alligo has entered a sustainability-linked loan agreement with Handelsbanken regarding existing loans totaling SEK 2.3 billion. The agreement connects the loans to the Group's sustainability targets for responsible supplier relationships, equality as well as reduced electricity and energy consumption.
  • On 5 July, Alligo received regulatory approval for the acquisitions of Hämeen Teollisuuspalvelu Oy and Riihimäen Teollisuuspalvelu Oy. The acquisitions were completed on 1 August.
  • On 1 July, Alligo completed the acquisitions of T. Brantestig Svetsmaskinservice AB and Aktiebolaget Sundholm Welding.

Events after the end of the period

  • On 14 October, Alligo signed an agreement to acquire 100 per cent of the shares in Corema Svets & Industriprodukter AB. Corema is a full-service supplier of welding and industrial products, as well as fasteners, with operations in Gothenburg and Sundsvall. Together with its subsidiaries, the company generates annual revenue of approximately MSEK 155 with good profitability and has 25 employees.

Comments from the CEO

"We are continuing to see positive signs on the market, but nothing as yet that has been reflected in sales."

"We adapted our cost structure at an early stage and we have generally been successful in maintaining our margins in each product segment, although a less favourable customer mix has affected the gross margin."

"To drive profitable growth even in a weak market, we continue with cost reductions but also invest heavily in developing and strengthening our offering, improving sales work and implementing strategic acquisitions."

"During the third quarter, we completed four acquisitions with combined annual revenue of approximately MSEK 220. After the end of the quarter, we also signed an agreement to acquire Corema Svets & Industriprodukter AB, which is a full-service supplier of welding and industrial products, as well as fasteners, with an annual revenue of approximately MSEK 155."

Presentation of the interim report for the third quarter 2024

Alligo publishes its interim report for the third quarter on Thursday, 24 October 2024, at 08:00 a.m. CEST. In conjunction with this, Alligo is pleased to issue this invitation to a webcast conference call in which President & CEO Clein Johansson Ullenvik and CFO Irene Wisenborn Bellander will present the report and answer any subsequent questions. The presentation will be held in English.

Date and time: Thursday, October 24, 2024, at 11:00 a.m. CEST

Weblink: https://edge.media-server.com/mmc/p/gnu6zdiw

Telephone conference: https://register.vevent.com/register/BI22da7cdb37f5409db26b109336a0750c

Participants need to register in advance of the conference call using the link above. Upon registering, each participant will be provided with Participant Dial-In Number, and a unique Personal PIN.

Contact information:
Clein Johansson Ullenvik, President & CEO
Irene Wisenborn Bellander, CFO
Tel +46 8 712 00 00
ir@alligo.com

This information is information that Alligo AB (publ) is obliged to publish under the EU Market Abuse Regulation. The information was submitted for publication through the agency of the Chief Executive Officer on 24 October 2024 at 08:00 CEST.

About Alligo AB
Alligo is a leading player within workwear, personal protective equipment, tools, and consumables in the Nordic region. Sales are mainly made through the strong concept brands Swedol in Sweden and TOOLS in Norway and Finland. The Group has approximately 2,400 employees and an annual revenue of SEK 9.3 billion. The share is listed on Nasdaq Stockholm. Read more at alligo.com


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.